You are viewing: Thailand Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The Thailand Leukapheresis Market was valued at $0.48 Million in 2026 and projected to reach to $0.7 Million by 2031, representing a compound annual growth rate of CAGR 7.8%. Thailand's leukapheresis market is positioned as a niche but strategically important segment within Asia Pacific healthcare.

Thailand Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Thailand Leukapheresis Market Trends and Insights

  • Valued at $0.48 million in 2026, Thailand's market is expected to expand to $0.70 million by 2031, reflecting a compound annual growth rate of 7.8%.
  • This growth trajectory in Thailand is driven by increasing adoption of cell therapy technologies and rising prevalence of hematologic malignancies requiring apheresis procedures. The leukapheresis market in Thailand benefits from improving healthcare infrastructure and growing investment in advanced therapeutic technologies.
  • Thailand's healthcare sector is progressively integrating sophisticated blood cell separation techniques to support both domestic clinical demand and emerging CAR-T cell therapy programs.
  • Between 2026 and 2031, Thailand is expected to see gradual expansion in treatment centers equipped with leukapheresis capabilities, particularly in major urban centers. Thailand's market growth is supported by regional medical tourism and cross-border patient flows, which enhance demand for specialized apheresis services.
  • As Thailand continues to strengthen its position as a regional healthcare hub, the leukapheresis market is anticipated to benefit from both local clinical adoption and international patient referrals seeking advanced cell therapy treatments..

Key Market Statistics

  • CAGR (2026-2031) CAGR 7.8%
  • Market Size, 2026 ~USD 0.48 Million
  • Forecast, 2031 ~USD 0.7 Million
  • Country Thailand

Thailand Leukapheresis Market Overview

Market Valuation Growth :

Thailand's leukapheresis market is valued at $0.48 million in 2026 and is projected to reach $0.70 million by 2031, demonstrating steady expansion within the Southeast Asian healthcare sector.

Consistent CAGR Performance :

The Thai market exhibits a 7.8% compound annual growth rate from 2026-2031, slightly below the global average of 8.9%, indicating moderate but sustainable market development.

Cell Therapy Adoption :

Increasing adoption of advanced cell therapy technologies in Thailand is driving demand for leukapheresis procedures, supported by growing healthcare infrastructure investments and clinical research initiatives.

Hematologic Disease Prevalence :

Rising prevalence of hematologic malignancies and blood disorders in Thailand is creating sustained demand for leukapheresis services, positioning the market as a critical component of oncology care.

Thailand Leukapheresis Market Dynamics

  • The market's 7.8% CAGR reflects growing clinical adoption of cell therapy technologies and increasing investment in advanced medical infrastructure across Thai healthcare institutions.
  • Government initiatives promoting medical tourism and biotechnology development are expected to accelerate market penetration. Looking ahead to 2031, Thailand's market will benefit from rising hematologic disease prevalence, expanding patient access to CAR-T and other cell-based therapies, and strengthening partnerships between local hospitals and international biotech firms.
  • However, market growth will be tempered by limited reimbursement frameworks and the concentration of advanced treatment centers in major urban areas, requiring targeted policy interventions to ensure broader market expansion..

Related Ecosystem

Key Takeaways

  • Thailand's leukapheresis market is valued at $0.48 million in 2026 and is projected to reach $0.70 million by 2031 at a 7.8% CAGR.
  • Thailand's market growth is driven by increasing adoption of CAR-T cell therapies and rising hematologic malignancy prevalence requiring apheresis procedures.
  • Thailand's healthcare infrastructure improvements and position as a regional medical tourism hub support expanding leukapheresis service capacity.
  • Thailand's market expansion is expected to concentrate in major urban centers with advanced treatment facilities between 2026 and 2031.

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

Thailand Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

THAILAND: LEUKOPAKS MARKET, BY END USER, 2024–2031

Segment20242025202620272028202920302031CAGR (%)
ACADEMIC & RESEARCH INSTITUTES0.890.971.071.181.31.431.591.7610.5
CONTRACT RESEARCH ORGANIZATIONS0.050.050.060.060.070.070.080.098.1
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES0.270.30.330.370.410.460.520.5912.1
TOTAL1.21.321.461.611.781.972.192.4310.8

THAILAND: LEUKAPHERESIS MARKET, BY END USER, 2024–2031

Segment20242025202620272028202920302031CAGR (%)
ACADEMIC & RESEARCH INSTITUTES0.070.080.080.090.090.10.110.128.4
BLOOD COMPONENT PROVIDERS & BLOOD CENTERS0.280.30.330.360.390.420.460.519.8
HOSPITALS & TRANSFUSION CENTERS0.110.120.130.140.150.170.180.199.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES0.040.050.050.050.060.060.060.077.2
TOTAL0.510.550.590.640.690.750.810.889.3

Target Audience

  • Medical Device Manufacturers : Leukapheresis equipment and consumable suppliers need Thailand-specific market data to assess market size, growth potential, and localization requirements for product distribution and clinical adoption.
  • Biopharmaceutical Companies : Cell therapy and CAR-T developers require detailed Thailand market insights to evaluate commercial viability, patient population size, and healthcare infrastructure readiness for therapy launches.
  • Healthcare Investors & PE Firms : Investment professionals need country-level market analysis to identify growth opportunities, assess risk-return profiles, and evaluate acquisition targets within Thailand's emerging leukapheresis sector.
  • Hospital & Clinical Networks : Thai healthcare institutions require market intelligence to benchmark service offerings, understand demand trends, and make informed capital investment decisions for leukapheresis capabilities.
  • Healthcare Consultants & Advisors : Strategy consultants supporting clients in Thailand need localized market data to develop business plans, competitive strategies, and market entry approaches for leukapheresis-related services.

Key Companies in the Thailand Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

Reasons to Buy this Report

  • Thailand-Specific Market Sizing : Obtain precise market valuation data for Thailand ($0.48M in 2026, $0.70M in 2031) with country-level CAGR analysis to support localized business planning and investment decisions.
  • Competitive Landscape Intelligence : Identify key players, market share distribution, and competitive dynamics specific to Thailand's leukapheresis sector to inform market entry strategies and partnership opportunities.
  • Regulatory & Reimbursement Insights : Understand Thailand's unique regulatory environment, healthcare reimbursement policies, and government initiatives affecting leukapheresis adoption and market accessibility.
  • Growth Driver Analysis : Analyze Thailand-specific factors driving 7.8% CAGR, including cell therapy adoption rates, disease prevalence trends, and healthcare infrastructure development in the country.
  • Strategic Market Positioning : Develop targeted go-to-market strategies for Thailand by understanding local patient demographics, hospital capabilities, clinical adoption barriers, and emerging opportunities in the region.

Frequently asked questions

What is the current market size of leukapheresis in Thailand?

Thailand's leukapheresis market was valued at $0.48 million in 2026 and is expected to grow to $0.70 million by 2031.

What is the projected growth rate for Thailand's leukapheresis market?

Thailand's leukapheresis market is projected to grow at a compound annual growth rate (CAGR) of 7.8% from 2026 to 2031.

What factors are driving growth in Thailand's leukapheresis market?

Thailand's market growth is driven by increasing adoption of CAR-T cell therapies, rising prevalence of hematologic malignancies, improving healthcare infrastructure, and Thailand's position as a regional medical tourism destination.

Which regions in Thailand are expected to see the most leukapheresis market growth?

Thailand's market expansion is expected to concentrate in major urban centers with advanced healthcare facilities and treatment infrastructure between 2026 and 2031.

How does Thailand's leukapheresis market compare to other Asia Pacific countries?

Thailand's leukapheresis market at $0.48 million in 2026 represents a growing niche segment within the broader Asia Pacific region, with steady expansion driven by regional healthcare advancement and medical tourism.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status